Anus cancer

Summary

Anus cancer (MONDO:0001879) is a cancer and 7 clinical trials. Top therapeutic interventions include indocyanine green acid form and cod liver oil. A subtype of anus neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anus cancer
Mondo ID	MONDO:0001879
DOID	DOID:14110
NCIT	C7379
UMLS	C0153446
MedGen	56303
GARD	0009300
Anatomy (UBERON)	UBERON:0001245
Is cancer (heuristic)	yes

Also known as: anus cancer · cancer of anus · malignant anal neoplasm · malignant anal tumor · malignant anal tumour · malignant anus neoplasm · malignant neoplasm of anus · malignant neoplasm of the anus · malignant tumor of anus · malignant tumor of the anus · malignant tumour of anus · malignant tumour of the anus

Disease family

This is a subtype of anus neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › rectal neoplasm › anus neoplasm › anus cancer

Related subtypes (2): anal gland neoplasm, benign neoplasm of anus

Subtypes (4): anus lymphoma, anus sarcoma, anal carcinoma, anal melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02997553	PHASE3	COMPLETED	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
NCT04534075	PHASE3	COMPLETED	Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
NCT02865135	PHASE1/PHASE2	COMPLETED	Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
NCT04066894	PHASE2	TERMINATED	Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
NCT03133286	Not specified	COMPLETED	Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
NCT04109573	Not specified	UNKNOWN	Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)
NCT04905030	Not specified	UNKNOWN	Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INDOCYANINE GREEN ACID FORM	4	2
COD LIVER OIL	-1	1